日本子宫内膜癌机器人手术的现状
The current status of robotic surgery for endometrial cancer in Japan.
作者信息
Gota Tomoko, Tomio Kensuke, Kurose Taichi, Saito Risa, Nara Ryoken, Kin Sohmi, Hoshiba Minami, Ogata Yuri, Nakanishi Misao, Takamoto Maya, Sadatsuki Miyuki, Oishi Hajime
机构信息
Department of Obstetrics and Gynecology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
出版信息
Glob Health Med. 2022 Feb 28;4(1):21-25. doi: 10.35772/ghm.2021.01077.
The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA, USA) was approved in 2009 by the Japanese Ministry of Health, Labor, and Welfare. In gynecology, robotic surgery for hysterectomy for benign indications and early-stage endometrial cancer has been covered by National Health Insurance since 2018. In a context where the da Vinci surgical system has prevailed in urology departments in Japan, gynecological robotic surgery has spread rapidly once it was covered by insurance. Although minimally invasive gynecologic surgery (minimally invasive surgery, or MIS) in Japan has a specific context, there are several problems with its safety, surgeon education, and cost in Japan. To maximize the many advantages of robotic surgery, its effectiveness needs to be carefully evaluated and this new technology needs to be safely incorporated in practice.
达芬奇手术系统（直观外科公司，美国加利福尼亚州桑尼维尔）于2009年获得日本厚生劳动省批准。在妇科领域，自2018年起，用于良性指征子宫切除术和早期子宫内膜癌的机器人手术已纳入国民健康保险范围。在达芬奇手术系统在日本泌尿外科盛行的背景下，妇科机器人手术一旦被纳入保险范围便迅速普及。尽管日本的微创妇科手术（微创手术，或MIS）有其特定背景，但在安全性、外科医生培训及成本方面仍存在若干问题。为充分发挥机器人手术的诸多优势，需要仔细评估其有效性，并将这项新技术安全地应用于实际操作中。
Zotero 插件